Clinical trial
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With…
NCT00004998 · Agouron Pharmaceuticals, Industry · Suspended
Key facts
| NCT number | NCT00004998 |
|---|---|
| Title | Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients |
| Official title | A Phase II, Open-Label Study of AG1549 in Combination With Other Antiretroviral Agents in Treatment-Naive HIV-Infected Patients |
| Lead sponsor | Agouron Pharmaceuticals, Industry |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate |
| Enrollment | 30 |
| Start date | Nov 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Dominican Republic, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: